BioSkryb Genomics Acquires Exclusive License for Cutting-edge Methylation Patent
Deal News | Aug 20, 2025 | Anzu Partners LLC
BioSkryb Genomics has executed an exclusive license agreement for a revolutionary methylation patent, which is co-owned by Stanford University and the Chan Zuckerberg Biohub. This breakthrough technology will enable the company to develop the world's first single-cell, five-base genome. The license secured by BioSkryb aims to advance single-cell and ultra–low-input multi-omic solutions in the field of genomics. The patent was acquired with the support of Anzu Partners LLC, a private equity firm that specializes in accelerating innovation in breakthrough technologies.
Sectors
- Genomics
- Private Equity
Geography
- United States – The companies and institutions mentioned, such as Stanford University and the Chan Zuckerberg Biohub, are based in the United States. BioSkryb Genomics also operates within this geography.
Industry
- Genomics – This industry is relevant as the article discusses BioSkryb Genomics' acquisition of a patent important in genomics research, particularly in single-cell genome solutions.
- Private Equity – Anzu Partners LLC, a private equity firm, is identified as a backer of BioSkryb's initiatives, illustrating the intersection of finance and biotechnology advancements.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| BioSkryb Genomics | Target Company | Company | A pioneer in single-cell and ultra–low-input multi-omic solutions, now enhancing capabilities with the exclusive license. |
| Anzu Partners LLC | Private Equity Firm | Company | Private equity firm backing BioSkryb's acquisition to support groundbreaking genomic technology. |
| Stanford University | Patent Co-owner | Institution | Co-owner of the methylation patent licensed by BioSkryb Genomics. |
| Chan Zuckerberg Biohub | Patent Co-owner | Institution | Co-owner of the methylation patent licensed to BioSkryb Genomics. |